Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
Milestones underscore clinical progress and strengthen commercial foundation LOS GATOS, Calif., April 8, 2026 /PRNewswire/ — Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today
